Patents by Inventor Brandon Reid Rosen

Brandon Reid Rosen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha
    Patent number: 11787762
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: October 17, 2023
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Thomas Andre Fournier, Balint Gal, Tezcan Guney, Karl T. Haelsig, Clayton Hardman, Steven Donald Jacob, Jenna Leigh Jeffrey, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Artur Karenovich Mailyan, Debashis Mandal, Guillaume Mata, Hyunyoung Moon, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Zhang Wang, Xuelei Yan, Kai Yu
  • Modulators of 5?-nucleotidase, ecto and the use thereof
    Patent number: 11667662
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: June 6, 2023
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ui Sharif
  • INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF
    Publication number: 20230159466
    Abstract: The present disclosure is directed to compounds that are inhibitors of HIF-2? having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.
    Type: Application
    Filed: October 28, 2022
    Publication date: May 25, 2023
    Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Matthew EPPLIN, Jeremy FOURNIER, Balint GAL, Clayton HARDMAN, Artur Karenovich MAILYAN, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Dongdong LIU, Guillaume MATA, Masa PODUNAVAC, Jay Patrick POWERS, Brandon Reid ROSEN, Kai YU
  • TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA
    Publication number: 20230021476
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Application
    Filed: June 8, 2022
    Publication date: January 26, 2023
    Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Matthew EPPLIN, Jeremy Thomas Andre FOURNIER, Balint GAL, Tezcan GUNEY, Karl T. HAELSIG, Clayton HARDMAN, Steven Donald JACOB, Jenna Leigh JEFFREY, Jaroslaw KALISIAK, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Artur Karenovich MAILYAN, Debashis MANDAL, Guillaume MATA, Hyunyoung MOON, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Zhang WANG, Xuelei YAN, Kai YU
  • INHIBITORS OF HIF-2ALPHA
    Publication number: 20230024438
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Application
    Filed: December 3, 2020
    Publication date: January 26, 2023
    Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Jeremy Thomas Andre FOURNIER, Tezcan GUNEY, Steven Donald JACOB, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Debashis MANDAL, Guillaume MATA, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Xuelei YAN
  • Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2?
    Patent number: 11407712
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: August 9, 2022
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Thomas Andre Fournier, Balint Gal, Tezcan Guney, Karl T. Haelsig, Clayton Hardman, Steven Donald Jacob, Jenna Leigh Jeffrey, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Artur Karenovich Mailyan, Debashis Mandal, Guillaume Mata, Hyunyoung Moon, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Zhang Wang, Xuelei Yan, Kai Yu
  • PROCESSES FOR PREPARING AMINOPYRIMIDINE COMPOUNDS
    Publication number: 20220235031
    Abstract: Provided herein are improved processes for preparing aminopyrimidine compounds of Formula (I). The disclosed processes advantageously proceed through a ?-diketoester intermediate of Formula (A) and avoid the direct linking of a pyrimidine and phenyl moieties. The disclosed methods significantly increase yield of the desired compounds and simplifies the synthetic route.
    Type: Application
    Filed: June 5, 2020
    Publication date: July 28, 2022
    Inventors: Manmohan Reddy LELETI, Dillon Harding MILES, Brandon Reid ROSEN, Ehesan Ul SHARIF, Jay Patrick POWERS
  • INHIBITORS OF ARG1 AND/OR ARG2
    Publication number: 20220016143
    Abstract: Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 20, 2022
    Inventors: Joel BEATTY, Eric Thomas NEWCOMB, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Corinne Nicole FOLEY, Rebecca Louise GRANGE, Tezcan GUNEY, Steven Donald JACOB, Jaroslaw KALISIAK, Manmohan Reddy LELETI, Erick Allen LINDSEY, Debashis MANDAL
  • Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
    Patent number: 11220492
    Abstract: A compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors having Formula (I) and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: January 11, 2022
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Manmohan Reddy Leleti, Dillon Harding Miles, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF
    Publication number: 20210371449
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: March 19, 2021
    Publication date: December 2, 2021
    Inventors: Laurent Pierre Paul DEBIEN, Juan Carlos JAEN, Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
  • TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA
    Publication number: 20210317079
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Application
    Filed: March 18, 2021
    Publication date: October 14, 2021
    Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Matthew EPPLIN, Jeremy Thomas Andre FOURNIER, Balint GAL, Tezcan GUNEY, Karl T. HAELSIG, Clayton HARDMAN, Steven Donald JACOB, Jenna Leigh JEFFREY, Jaroslaw KALISIAK, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Artur Karenovich MAILYAN, Debashis MANDAL, Guillaume MATA, Hyunyoung MOON, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Zhang WANG, Xuelei YAN, Kai YU
  • QUINAZOLINE-PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS
    Publication number: 20210214346
    Abstract: A compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Application
    Filed: May 16, 2018
    Publication date: July 15, 2021
    Inventors: Manmohan Reddy LELETI, Dillon Harding MILES, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
  • Inhibitors of adenosine 5?-nucleotidase
    Patent number: 11058704
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: July 13, 2021
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
    Patent number: 11045472
    Abstract: Compounds of Formula I that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing compounds of Formula I and methods for synthesizing compounds of Formula I, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: June 29, 2021
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Manmohan Reddy Leleti, Dillon Harding Miles, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif, Rhiannon Thomas-Tran
  • PYRIDONE A2R ANTAGONISTS
    Publication number: 20210161898
    Abstract: Compound that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Application
    Filed: July 26, 2019
    Publication date: June 3, 2021
    Inventors: Manmohan Reddy LELETI, Debashis MANDAL, Dillon Harding MILES, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
  • Modulators of 5?-nucleotidase, ecto and the use thereof
    Patent number: 11001603
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: May 11, 2021
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • Modulators of 5?-nucleotidase, ecto and the use thereof
    Patent number: 10981944
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: April 20, 2021
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF
    Publication number: 20210002322
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: September 1, 2020
    Publication date: January 7, 2021
    Inventors: Laurent Pierre Paul DEBIEN, Juan Carlos JAEN, Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
  • INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE
    Publication number: 20200222441
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: October 2, 2017
    Publication date: July 16, 2020
    Inventors: Laurent Pierre Paul DEBIEN, Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
  • QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS
    Publication number: 20200069689
    Abstract: Compounds that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Application
    Filed: May 3, 2018
    Publication date: March 5, 2020
    Inventors: Manmohan Reddy LELETI, Dillon Harding MILES, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF, Rhiannon THOMAS-TRAN